NO942641L - Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav - Google Patents

Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav

Info

Publication number
NO942641L
NO942641L NO942641A NO942641A NO942641L NO 942641 L NO942641 L NO 942641L NO 942641 A NO942641 A NO 942641A NO 942641 A NO942641 A NO 942641A NO 942641 L NO942641 L NO 942641L
Authority
NO
Norway
Prior art keywords
phosphatidylinositol
kinase
wortmannin
inhibition
analogs
Prior art date
Application number
NO942641A
Other languages
English (en)
Other versions
NO942641D0 (no
Inventor
Rosanne Bonjouklian
Garth Powis
Chris John Vlahos
Original Assignee
Lilly Co Eli
Arizona Board Of Regents The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Arizona Board Of Regents The filed Critical Lilly Co Eli
Publication of NO942641D0 publication Critical patent/NO942641D0/no
Publication of NO942641L publication Critical patent/NO942641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)

Abstract

Wortmannin og visse analoger derav er inhibitorer av fosfatidylinositol 3-kinase. Forbindelsene er spesielt nyttige for inhibering av fosfatidylinositol 3-kinase i pattedyr og for behandling av fosfatidylinositol 3-kinase-avehengige tilstander, spesielt neoplasmer, i pattedyr.
NO942641A 1993-07-19 1994-07-14 Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav NO942641L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Publications (2)

Publication Number Publication Date
NO942641D0 NO942641D0 (no) 1994-07-14
NO942641L true NO942641L (no) 1995-01-20

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942641A NO942641L (no) 1993-07-19 1994-07-14 Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav

Country Status (16)

Country Link
US (1) US5378725A (no)
EP (1) EP0635268A1 (no)
JP (1) JPH0753370A (no)
KR (1) KR950002755A (no)
CN (1) CN1111127A (no)
AU (1) AU678831B2 (no)
CA (1) CA2128046A1 (no)
CZ (1) CZ283806B6 (no)
HU (1) HUT67667A (no)
IL (1) IL110325A0 (no)
NO (1) NO942641L (no)
PH (1) PH30794A (no)
PL (1) PL304317A1 (no)
RU (1) RU94026082A (no)
TW (1) TW287102B (no)
ZA (1) ZA945103B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
DE69932510T2 (de) * 1998-03-24 2007-02-15 Chugai Seiyaku K.K. Vaskularisierungsinhibitoren
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) * 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU2001265137B2 (en) * 2000-05-30 2007-06-14 Indiana University Research And Technology Corporation Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
AU2003248927A1 (en) * 2002-07-10 2004-01-23 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1601759A4 (en) * 2003-03-07 2007-02-14 Gamida Cell Ltd EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING PI-3 KINASE MODULATORS
BRPI0409681A (pt) * 2003-04-23 2006-04-18 Wyeth Corp derivados de wortmanina solúveis em água
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
KR20060066722A (ko) 2003-08-13 2006-06-16 쿠도스 파마슈티칼스 리미티드 아미노피론 및 ａｔｍ억제제로서의 이의 용도
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
RU2408596C2 (ru) 2004-09-20 2011-01-10 Кудос Фармасьютикалс Лимитед Ингибиторы днк-пк
TW200626610A (en) * 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
JP2008529995A (ja) 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
EP1886138A4 (en) * 2005-05-11 2009-04-15 Genetic Technologies Ltd METHODS FOR ENRICHING FETAL CELLS
JP2008545670A (ja) * 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
WO2008056368A2 (en) * 2006-11-09 2008-05-15 Gamida-Cell Ltd. Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) * 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
EP0635268A1 (en) 1995-01-25
CA2128046A1 (en) 1995-01-20
KR950002755A (ko) 1995-02-16
HU9402128D0 (en) 1994-09-28
US5378725A (en) 1995-01-03
AU678831B2 (en) 1997-06-12
PL304317A1 (en) 1995-01-23
CN1111127A (zh) 1995-11-08
IL110325A0 (en) 1994-10-21
PH30794A (en) 1997-10-17
HUT67667A (en) 1995-04-28
JPH0753370A (ja) 1995-02-28
CZ169294A3 (en) 1995-02-15
RU94026082A (ru) 1996-05-20
ZA945103B (en) 1996-03-27
TW287102B (no) 1996-10-01
AU6754094A (en) 1995-01-27
CZ283806B6 (cs) 1998-06-17
NO942641D0 (no) 1994-07-14

Similar Documents

Publication Publication Date Title
AU657166B2 (en) Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
NO942641D0 (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
SE8503680D0 (sv) Indolderivat
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
GR3021420T3 (en) 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
DE69516866D1 (de) Stereochemische wortmanninderivate
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
NO996578L (no) Urokinase-inhibitorer
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
MX9303145A (es) 7-(2-aminoetil)benzotiazolonas.
DE69102936D1 (de) Bis(alkyl-substituierte-4-hydroxyphenylthio)alkan-Analoga als Inhibitoren der Kataraktentstehung.
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
NO891703L (no) Farmasoeytiske sammensetninger for behandling av psoriasis.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ES2171553T3 (es) Derivados de quinoxalina utiles en terapia.
DK318589A (da) 19-substituerede progesteron-derivater, anvendelige som 19-hydroxylase-inhibitorer
AU558461B2 (en) Carbamyloxybenzhyrol derivatives
ES8707495A1 (es) Un procedimiento para preparar derivados de azetidinona
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
EP0521080A4 (en) Synergistic compositions
IL89901A (en) Strobilurine derivative
AR005866A1 (es) Composicion farmaceutica antioxidante